Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
54°
Partly Cloudy
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Macrogenics
(NQ:
MGNX
)
5.120
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Macrogenics
< Previous
1
2
Next >
MACROGENICS ALERT: Bragar Eagel & Squire, P.C. is Investigating MacroGenics, Inc. on Behalf of MacroGenics Stockholders and Encourages Investors to Contact the Firm
May 14, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against MacroGenics, Inc. (MGNX)
May 13, 2024
From
Kirby McInerney LLP
Via
Business Wire
MacroGenics to Participate in Upcoming Investor Conferences
May 13, 2024
From
MacroGenics, Inc.
Via
GlobeNewswire
MacroGenics Inc. (NASDAQ: MGNX) Leading the Way in Thursday Trading Based on Percentage Gain
April 04, 2024
Via
Investor Brand Network
MacroGenics Inc. (NASDAQ: MGNX) is a Stock Spotlight on 3/5
March 05, 2024
Via
Investor Brand Network
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against MacroGenics, Inc. and Encourages Investors to Contact the Firm
May 10, 2024
From
Schall Law
Via
GlobeNewswire
MacroGenics Announces Date of First Quarter 2024 Financial Results Conference Call
May 03, 2024
From
MacroGenics, Inc.
Via
GlobeNewswire
MacroGenics Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures
April 03, 2024
From
MacroGenics, Inc.
Via
GlobeNewswire
MacroGenics Inc. (NASDAQ: MGNX) is a Stock Spotlight on 2/12
February 12, 2024
Via
Investor Brand Network
MacroGenics Inc. (NASDAQ: MGNX) is a Stock Spotlight on 2/6
February 06, 2024
Via
Investor Brand Network
MacroGenics to Participate in Upcoming Investor Conferences
March 01, 2024
From
MacroGenics, Inc.
Via
GlobeNewswire
MacroGenics Announces Date of Fourth Quarter 2023 Financial Results Conference Call
February 27, 2024
From
MacroGenics, Inc.
Via
GlobeNewswire
MacroGenics to Participate in Upcoming Investor Conference
February 02, 2024
From
MacroGenics, Inc.
Via
GlobeNewswire
MacroGenics Inc. (NASDAQ: MGNX) is a Stock Spotlight on 2/1
February 01, 2024
Via
Investor Brand Network
MacroGenics Inc. (NASDAQ: MGNX) is a Stock Spotlight on 1/23
January 23, 2024
Via
Investor Brand Network
MacroGenics to Participate in Upcoming Investor Conference
January 08, 2024
From
MacroGenics, Inc.
Via
GlobeNewswire
MacroGenics to Participate in Upcoming Investor Conferences
November 02, 2023
From
MacroGenics, Inc.
Via
GlobeNewswire
MacroGenics Announces Date of Third Quarter 2023 Financial Results Conference Call
October 31, 2023
From
MacroGenics, Inc.
Via
GlobeNewswire
Elli Lilly Joins Big Pharma’s Multi-Billion-Dollar Oncology Race
October 10, 2023
Large pharmaceutical companies are increasingly investing in cancer treatment stocks, driven by the promise of medical breakthroughs and financial rewards. Eli Lilly became the latest Big Pharma giant...
Via
PressReach
MacroGenics Announces Achievement of $15 Million Milestone Related to Gilead’s Nomination of a Bispecific Research Program
September 05, 2023
From
MacroGenics, Inc.
Via
GlobeNewswire
MacroGenics to Participate in Upcoming Investor Conferences
August 31, 2023
From
MacroGenics, Inc.
Via
GlobeNewswire
MacroGenics Announces Date of Second Quarter 2023 Financial Results Conference Call
July 31, 2023
From
MacroGenics, Inc.
Via
GlobeNewswire
MacroGenics Announces Date of First Quarter 2023 Financial Results Conference Call
May 04, 2023
From
MacroGenics, Inc.
Via
GlobeNewswire
MacroGenics to Participate in Upcoming Investor Conferences
April 24, 2023
From
MacroGenics, Inc.
Via
GlobeNewswire
MacroGenics Earns $15 Million Milestone Following U.S. FDA Approval of ZYNYZ™ (retifanlimab-dlwr)
March 22, 2023
From
MacroGenics, Inc.
Via
GlobeNewswire
MacroGenics Announces Sale of TZIELD™ Royalty Interest for up to $200 Million
March 08, 2023
From
MacroGenics, Inc.
Via
GlobeNewswire
MacroGenics Announces Date of Fourth Quarter 2022 Financial Results Conference Call
March 07, 2023
From
MacroGenics, Inc.
Via
GlobeNewswire
MacroGenics to Participate in Upcoming Investor Conferences
March 02, 2023
From
MacroGenics, Inc.
Via
GlobeNewswire
MacroGenics Announces Preliminary Clinical Results from Single Arm Study of Lorigerlimab in Patients with Metastatic Castration-Resistant Prostate Cancer to be Presented at ASCO Genitourinary Cancers Symposium
February 13, 2023
From
MacroGenics, Inc.
Via
GlobeNewswire
MacroGenics to Participate in Upcoming Investor Conferences
February 06, 2023
From
MacroGenics, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.